about
Update on evidence for treatment with ranolazine in stable anginaInflammation in arterial diseasesPathophysiology and Treatments of Oxidative Injury in Ischemic Stroke: Focus on the Phagocytic NADPH Oxidase 2Update on Inflammatory Biomarkers and Treatments in Ischemic StrokePotential pathophysiological role for the vitamin D deficiency in essential hypertension.Update on the efficacy of statin treatment in acute coronary syndromes.Monoclonal antibodies for non-Hodgkin's lymphoma: state of the art and perspectives.Intraplaque Expression of C-Reactive Protein Predicts Cardiovascular Events in Patients with Severe Atherosclerotic Carotid Artery Stenosis.The role of the intraplaque vitamin d system in atherogenesis.Left atrial thrombosis in an anticoagulated patient after bioprosthetic valve replacement: Report of a caseProteasome inhibitors as immunosuppressants: biological rationale and clinical experience.Cannabinoid receptor type 2 activation in atherosclerosis and acute cardiovascular diseases.Implementation strategies of Systems Medicine in clinical research and home care for cardiovascular disease patients.Update on the role of neutrophils in atherosclerotic plaque vulnerability.The role of adipocytokines in atherogenesis and atheroprogression.Pathophysiology of ST-segment elevation myocardial infarction: novel mechanisms and treatments.Update on cardiotoxicity of anti-cancer treatments.Treatment with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors to Reduce Cardiovascular Inflammation and Outcomes.Anti-ApoA-1 IgG serum levels predict worse poststroke outcomes.Biophysical aspects and novel treatments of atrial fibrillation.Targeting Inflammation in Primary Cardiovascular Prevention.The Role of Adipocytokines in Coronary Atherosclerosis.The Role of Inflammation in Cardiovascular Outcome.Regulation and Function of Extracellular Nicotinamide Phosphoribosyltransferase/Visfatin.Impact of Red Wine Consumption on Cardiovascular Health.Decreased serum PCSK9 levels after ischaemic stroke predict worse outcomes.Vitamin D receptor is expressed within human carotid plaques and correlates with pro-inflammatory M1 macrophages.Pre-hospital alarm activation for STEMI patients undergoing primary percutaneous coronary intervention in the era of transradial procedures.The peak of blood lactate during the first 24h predicts mortality in acute coronary syndrome patients under extracorporeal membrane oxygenation.Prognostic value of PCSK9 levels in patients with acute coronary syndromes.Treatment with sulphated galactan inhibits macrophage chemotaxis and reduces intraplaque macrophage content in atherosclerotic mice.Serum osteopontin levels are upregulated and predict disability after an ischaemic stroke.Treatment with recombinant tissue plasminogen activator (r-TPA) induces neutrophil degranulation in vitro via defined pathways.Research update for articles published in EJCI in 2015.Treatment with anti-RANKL antibody reduces infarct size and attenuates dysfunction impacting on neutrophil-mediated injury.Treatment with Evasin-3 abrogates neutrophil-mediated inflammation in mouse acute pancreatitis.Monocyte count at onset predicts poststroke outcomes during a 90-day follow-up.High baseline C-reactive protein levels predict partial type 2 diabetes mellitus remission after biliopancreatic diversion.Levels of serum uric acid at admission for hypoglycaemia predict 1-year mortality.Update on the role of Pentraxin 3 in atherosclerosis and cardiovascular diseases.
P50
Q26852952-BB133EA4-D792-4C1E-98F2-EF511DB2C005Q26853576-B0A6AE66-1FEE-4694-9C11-7E76C6F7B289Q27005956-C70762CA-B621-4CFF-B038-EA4937F87542Q28078744-A3E38C40-F4C6-443A-8B62-49006B1E3739Q30363752-2E386316-CE79-4E9D-9986-BEFDFC526697Q34408660-BAD07EDE-6EB5-453C-B542-15D176613FE4Q34700655-3447E356-959F-4CB4-AAC1-666E399CDA8BQ37310466-F0078752-A7BC-460B-8AFD-9703F17E9A91Q37466074-7C47BF03-C542-4570-BE09-5A058BD8B7C6Q37576130-8F8E91B3-4155-4434-9EF0-648AAC48E8BBQ38021045-9F0A7731-B4EF-4D5B-9497-EECDDD66496BQ38253221-9D977511-2245-4893-8D6E-0A5DF9E41652Q38256763-8699DC3D-AE38-4F37-8BD1-56197BB6B576Q38266346-628082EF-6665-4AA8-96CF-EE567819D964Q38266348-0F4B8A4D-7DAD-4615-8DFA-C2B431660E92Q38626782-B898F64B-8364-4FB8-829F-4C1338DD0ED8Q38686222-33732CFD-00D0-45DD-ABC5-DEEE2D45EE69Q38750614-F0BABF4E-CB29-475C-AF75-347E576A704EQ38753862-80CF97B8-D647-4375-AA11-D9E945A03A95Q38902277-3669B808-E932-46A0-B08B-BF3A4577B64DQ38934217-46B144C6-7304-4393-90D1-FA128A5A6F14Q39129323-15DFCC95-D89E-4956-A768-EC00A49ADAC1Q39134471-FD0BAB3F-7837-48D1-BB81-59289535EE93Q39195646-6944F322-0CC9-4CC2-9B1F-2008D3BFF209Q39316111-3DC0E23A-9D92-4F08-A549-F0C7D8FDD813Q40530815-5AEC94BC-4204-47A1-BB0C-ABF6729DAE6CQ40609754-CC47446F-5AAA-49FD-B87F-0B749E899CC8Q40642564-D043F7EB-066C-4ECD-9AAE-7A1FD77A701FQ40646619-412B6721-9361-42E4-9681-40FBA2285C20Q41061002-AD7FAC1E-5E56-43BA-8170-A49F372F5CDCQ41079083-F0BCAF40-E506-496B-B246-3DF714BFCD7CQ41353520-81B7F912-63B4-4D51-8A3F-945F569101FBQ41588199-3394C1BC-BFBC-40C2-A8AA-9F45BF47BE9BQ41993135-539857FA-1E4E-45AA-8307-0C14D21FFD71Q46567372-9B90076C-3AAD-4AA0-B00F-B6459EB5C496Q46851060-FB2751D9-3D66-44B5-96E5-E41CECCD6409Q47303075-F21B129A-97DC-4810-A0A1-FE9EE150FF42Q47420280-1F0ECB60-1D28-4C84-9A4D-80F0D9AB4577Q47560571-923073E5-9D72-41CC-ABDD-33476C5ACDDDQ47626900-BD5F9396-8B03-446A-A820-45DD6297F1C4
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Federico Carbone
@ast
Federico Carbone
@en
Federico Carbone
@es
Federico Carbone
@nl
Federico Carbone
@sl
type
label
Federico Carbone
@ast
Federico Carbone
@en
Federico Carbone
@es
Federico Carbone
@nl
Federico Carbone
@sl
prefLabel
Federico Carbone
@ast
Federico Carbone
@en
Federico Carbone
@es
Federico Carbone
@nl
Federico Carbone
@sl
P1053
G-3650-2013
P106
P1153
36999901600
57200071492
P21
P31
P3829
P496
0000-0003-2957-4078
P569
2000-01-01T00:00:00Z